Official UK procurement notice
Compounded Aseptic Medicines · UK public procurement notice
Authority: The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS) (NHS & healthcare)
What is being bought4 lots · detail below
Published requirement descriptionThis Framework Agreement is for the supply of unlicensed, aseptically compounded, ready to use medicines in syringe and infusion bags
to NHS Scotland.
CPV: Pharmaceutical products
Lots and requirements (4)Procurement structure
4 lots · no lot values publishedLot #1Compounded Aseptic Medicines
Supply of the following aseptically compounded, ready to use medicines in syringes and infusions to NHS Scotland in a range of doses,
Atezolizumab
Cetuximab
Doxorubicin
Epirubicin
Infliximab (Inflectra®), (Remicade®), (Remsima®)
Nivolumab
Pembrolizumab
Pertuzumab
The Authority intends to awarded all presentations within this Lot to a single supplier.
Lot #2Compounded Aseptic Medicines
Supply of the following aseptically compounded, ready to use medicines in syringes and infusions to NHS Scotland in a range of doses,
Cyclophosphamide
Fluorouracil
Irinotecan
Methotrexate
Rituximab (Mabthera®), (Rixathon®), (Truxima®)
The Authority intends to awarded all presentations within this Lot to a single supplier
Lot #3Compounded Aseptic Medicines
Supply of the following aseptically compounded, ready to use medicines in syringes and infusions to NHS Scotland in a range of doses,
Bortezomib
Carboplatin
Cisplatin
Docetaxel
Gemcitabine
Oxaliplatin
Trastuzumab (Herceptin®), (Herzuma®)
Vincristine
The Authority intends to awarded all presentations within this Lot to a single supplier.
Lot #4Compounded Aseptic Medicines - All Other Presentations
Supply of the following aseptically compounded, ready to use medicines in syringes and infusions to NHS Scotland in a range of doses,
The molecules included in this Lot are,
Bevacizumab
Cytarabine
Infliximab (Zessly®)
Insulin
Methotrexate
Natalizumab
Nivolumab
Paclitaxel
Pemetrexed
Tocilizumab
Trastuzumab (Kanjinti®), (Ontruzant®)
Trastuzumab Subcutaneous
Vedolizumab
Each product line will be treated as an individual Lot and awarded as an unranked multi-supplier framework.
Procedure terms & legal framework
From the official record · publisher note attached- Procedure method
- Award procedure without prior publication of a call for competition
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Awarded without competition
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Framework agreement
- Who may use this agreement
- Not stated in the notice; call-off rights may be limited to the establishing authority
- Competition type
- Direct award (no call for competition)
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- Unspecified in notice
- First published
- 24 Feb 2025, 16:38 GMT
- Last source update
- 24 Feb 2025, 16:38 GMT
- Authority reference
NP38619- FTS notice number
2025/S 000-007093- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-04e7a2Find a Tender
- Why no open competition
- The procurement falls outside the scope of application of the directive
- Published justification
This VEAT notice is to advise the need for modification to meet the additional demands of the Scottish Health and Social Care sector
during the current Covid-19 pandemic and to maintain necessary supply due to circumstances unforeseen by the Authority in line with
Regulation 72(1)(c) of the Public Contracts (Scotland) Regulations 2015
- Review procedure
The notification will incorporate a ‘standstill period’ of a minimum of 10 clear calendar days (or a minimum of 15 if the communication
method used is not electronic) between the date on which the Authority despatches the VEAT notice and the date on which the Authority
proposes to conclude the relevant framework agreement.
The bringing of court proceedings against the authority during the standstill period will automatically continue the prohibition on entering
into the framework agreement until the court proceedings are determined, discontinued or disposed of, or the court, by interim order, brings
to an end the prohibition. The remedies that may be awarded by the courts before the framework agreement has been entered into include
the setting aside of the decision to award the framework agreement to the winning tenderer.
The bringing of court proceedings against the authority after the framework agreement has been entered into will not affect the framework
agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be
established. Otherwise, the remedies that may be awarded by the courts where the framework agreement has been entered into are limited
to the award of damages.
Publisher note: The estimated value(s) of the Framework Agreement referred to in Section V.2.4 (comprising three (4) Lots) cover(s) the twelve (12) month duration of the proposed modification period of the Framework Agreement. NOTE: To register your interest in this notice and obtain any additional information please visit the Public Contracts Scotland Web Site at https://www.publiccontractsscotland.gov.uk/Search/Search_Switch.aspx?ID=790498. (SC Ref:790498)
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast4 suppliers are admitted to this framework without individual award values or dates, see the supplier list below.
Contracts
Compounded Aseptic Medicines
- Signed
- 24 Feb 2025
- Value
- £13,653,346
- Status
- active
Compounded Aseptic Medicines
- Signed
- 24 Feb 2025
- Value
- £1,565,729
- Status
- active
Compounded Aseptic Medicines
- Signed
- 24 Feb 2025
- Value
- £1,064,777
- Status
- active
Compounded Aseptic Medicines - All Other Presentations
- Signed
- 24 Feb 2025
- Value
- £5,085,024
- Status
- active
Contracting authority & participating public bodies
Dispute resolution & review bodies
- Sheriff Court HouseReview body
Framework contractors & participating bidders
3 commercial parties on the notice- Baxter Healthcare LtdFramework contractor
- ITH Pharma LimitedFramework contractor
- Qualasept Limited t/a Bath ASUFramework contractor
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.